CAS Number: 104344-23-2
Chemical Name: (2RS) -1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol fumarate
Molecular Formula: C40H66N2O12
Molecular Weight: 767
Structure:
Specification:USP/EP/CP
Documentation/Status:GMP/JDMF/R0-CEP 2016-139-Rev 00
*The following content is generated by AI and is for reference only.
Bisoprolol Fumarate, identified by the CAS number 104344-23-2, is a widely prescribed pharmaceutical agent belonging to the beta-adrenergic blocking class. Chemically, it represents the fumarate salt of bisoprolol, designed to enhance stability and bioavailability compared to its free base form. The molecular formula for this compound is C₁₈H₃₁NO₄·C₄H₄O₄, reflecting the combination of the active drug molecule with fumaric acid. This specific salt formulation is crucial in clinical settings as it ensures consistent therapeutic effects when administered orally.
The primary medical application of Bisoprolol Fumarate lies in the management of cardiovascular disorders. It functions as a highly selective beta-1 adrenergic receptor antagonist, meaning it predominantly targets the heart while minimizing effects on the lungs, thereby reducing the risk of bronchospasm in patients with respiratory conditions. By blocking these receptors, the drug effectively lowers heart rate and reduces myocardial contractility, which subsequently decreases blood pressure and myocardial oxygen demand. Consequently, it serves as a first-line treatment for hypertension and chronic heart failure. In heart failure cases, it helps improve survival rates by preventing adverse remodeling of the heart muscle and alleviating symptoms such as shortness of breath and fatigue. Additionally, it is utilized in managing angina pectoris by extending exercise tolerance and reducing the frequency of chest pain episodes.
Beyond its therapeutic roles, Bisoprolol Fumarate is also significant in pharmacological research for studying sympathetic nervous system modulation. Its high selectivity makes it a preferred choice over non-selective beta-blockers for patients with comorbidities like asthma or peripheral vascular disease. The drug is typically available in tablet form, allowing for precise dosing adjustments tailored to individual patient needs. As a generic medication, it offers an affordable alternative to brand-name versions, increasing accessibility for global populations suffering from cardiovascular diseases. Continuous monitoring of renal function is often recommended during long-term therapy, as the drug is partially excreted unchanged by the kidneys. Overall, Bisoprolol Fumarate remains a cornerstone in modern cardiology, balancing efficacy with a favorable safety profile for millions of patients worldwide.